Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
12 November, 2019 13:58 IST
Aurobindo Pharma receives USFDA approval for Ibuprofen OTC Capsules
Source: IRIS | 02 Jul, 2018, 10.06AM
Comments  |  Post Comment

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200mg. Aurobindo’s Ibuprofen capsules are a generic equivalent of Pfizer's Advil Liqui-Gels Capsules. The product will be launched in Sep 2018.

Ibuprofen is used to relieve pain from various conditions such as headache, dental pain, muscular aches, and minor pain of arthritis. It is also used to reduce fever and to relieve from minor aches and pain due to the common cold or flu. The estimated market size of ibuprofen capsules OTC is USD 164 million for the twelve months ending March 2018, according to Nielsen data.

This is the 143rd ANDA (including 19 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 373 ANDA approvals (340 Final approvals including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.

Shares of the company gained Rs 2.6, or 0.43%, to trade at Rs 609.15. The total volume of shares traded was 9,865 at the BSE (9.54 a.m., Monday).

Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Security Code type    into this box
Company Update
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer